BioNumerik Reports Preclinical Antitumor Data On Two Novel Supercomputer Engineered Anticancer Agents At 89th Annual AACR Conference

- Novel class of highly lipophilic camptothecins, known as Karenitecins, demonstrates potent oral antitumor activity, acceptable safety and appear to be insensitive to common tumor-associated drug resistance mechanisms

- BioNumerik's novel chemoprotecting agent BNP7787 appears to completely protect against major toxicities associated with widely used platinum anticancer drugs such as cisplatinum

New Orleans, LA - March 30, 1998 -- BioNumerik Pharmaceuticals, Inc. this week presented new research results on two novel supercomputer-engineered small molecule agents designed to help address significant existing problems in current cancer therapy. These results continue to strengthen the correlation between actual experimental observations and the computational simulations provided by BioNumerik's innovative supercomputer simulations and mechanism based approach to new pharmaceutical discovery and development.

Regarding BioNumerik's BNP7787 and Karenitecins, Martin D. Abeloff, M.D., Director of the Johns Hopkins Oncology Center, stated, "These drugs have the potential to make a significant impact on current cancer therapy. The data reported by BioNumerik is particularly meaningful because the discovery and design of both of these agents was supported by BioNumerik's mechanism based computational studies and supercomputer simulations."

Frederick H. Hausheer, M.D., BioNumerik's Chairman and Chief Executive Officer, presented these findings at the 89th Annual Meeting of the American Association for Cancer Research held March 28 - April 1, 1998.

In a presentation titled "Karenitecins: A Novel Class of Orally Active Highly Lipophilic Topoisomerase I Inhibitors", the results presented by BioNumerik of studies conducted in BALB/c mice indicate that orally administered Karenitecin had excellent antitumor activity against solid tumors (prostate, colon, breast, lung) and had superior antitumor potency compared to existing camptothecin deriva

Contact: Neil Cohen
212-696-4455 x. 205
Noonan/Russo Communications

Page: 1 2 3 4 5

Related medicine news :

1. BioNumerik Reports Data On Two Novel Supercomputer Engineered Anticancer Agents At 90th Annual Meeting Of The AACR
2. BioNumerik Reports The Supercomputer Supported Discovery Of New, Non-Toxic Chemotherapy Protecting Agent
3. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
4. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
5. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference
6. UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer
7. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
8. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
9. Changes In Levels Of LDLc From Pre- To Post-Menopausal Years Not Valuable Indicator Of Heart Disease, Reports University Of Pittsburgh Researcher
10. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
11. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports

Post Your Comments:

(Date:10/17/2019)... ... October 17, 2019 , ... Dr. Parsa Mohebi, the ... Angeles and Beverly Hills, is reminding patients interested in undergoing a hair transplant that ... , According to Dr. Mohebi, “The holidays are a time for friends and family ...
(Date:10/15/2019)... Va. (PRWEB) , ... October 15, 2019 , ... ... Complying with FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, Tuesday, October ... recent Instructions for Use (IFU) guidance have on new drug applications and biologics ...
(Date:10/11/2019)... ... October 11, 2019 , ... Inland Detox, Inc. has just moved ... location has incredible views of the Temecula Valley and it’s the perfect place for ... facility offers both private rooms as well as double occupancy rooms, a 2nd home ...
(Date:10/10/2019)... , ... October 10, 2019 , ... ... Annual Conference, Nutrition 21 was excited to hear the significant results of an ... blood flow impact of Nitrosigine®. The clinical study poster entitled “The Acute Effects ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. Amir HagShenas of Silicon ... Jose, CA experience relief from this common and treatable condition. Dr. HagShenas’ goal is ... adults from living with uncomfortable symptoms, including tender and bleeding gums, and to prevent ...
Breaking Medicine News(10 mins):
(Date:10/19/2019)... ... ... Hospital M&A activity held steady with 21 transactions in both the second and ... quarter was down 20% compared with the same period in 2018, when 25 deals ... $5.0 billion, a 291% increase. Year over year, Q3:19 spending was down 41% versus ...
(Date:10/17/2019)... (PRWEB) , ... October 17, 2019 , ... ... a patient receiving the right treatment before it progresses further. With many patients ... resources that can help their correct identification of skin cancer be extremely valuable. ...
(Date:10/11/2019)... ... 11, 2019 , ... The 'W' Initiative, a flagship women ... Health Month. The plans are aimed at improving community awareness on health issues ... to health checks and encouraging healthy lifestyle habits. , Slated to run all ...
Breaking Medicine Technology:
Cached News: